AI Assistant
Blog
Pricing
Log In
Sign Up
Fedratinib, the first selective JAK2 inhibitor approved for treatment of myelofibrosis – an option beyond ruxolitinib
Details
Cite
Export
Add to List
This content is not available in your region!
Continue researching
here.